Oxytocin’s Role in Modulating Thyroid Function and Mental Health in Obesity: Insights from an 8-Week Clinical Trial

Highlight

• Intranasal oxytocin administration for 6 weeks increases the free T3/free T4 ratio in adults with obesity without altering absolute TSH, free T3, or free T4 levels.
• Oxytocin impacts the relationship between thyroid hormone ratio changes and mental health-related quality of life (MHQoL), showing a trend toward positive correlation.
• This study supports a novel link between oxytocin, thyroid function modulation, and mental health improvements in a euthyroid obese population.
• Findings may guide future interventions targeting neuroendocrine pathways to enhance psychological well-being in obesity management.

Study Background

Obesity represents a major global health challenge, frequently accompanied by comorbid psychiatric conditions such as depression and anxiety, which impair quality of life and complicate treatment. Oxytocin (OXT), a neuropeptide traditionally recognized for roles in social bonding and reproduction, has emerged as a modulator of appetite, anxiety, and mood. Preclinical and early human studies suggest OXT’s potential as a therapeutic agent for obesity and associated neuropsychological symptoms. However, the underlying endocrine mechanisms mediating OXT’s psychotropic effects remain largely elusive.

Thyroid hormones significantly influence mood and cognitive function. Notably, alterations in the peripheral thyroid hormone metabolism, reflected by the ratio of free triiodothyronine (fT3) to free thyroxine (fT4), have been implicated in mood disorders such as depression. Lower fT3/fT4 ratios, due to reduced peripheral conversion of T4 to the active T3, correlate with increased depressive symptoms, even in euthyroid states. Whether OXT modulates this axis in humans and contributes to mental health improvements via thyroid function has not been investigated prior to this study.

Study Design

This investigation constitutes a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial conducted at a tertiary academic center. Sixty-one adults with obesity (body mass index criteria unspecified) were randomized to receive intranasal OXT (24 international units) or placebo four times daily over an 8-week period.

Key endpoints included fasting thyroid hormone measurements at 6 weeks — specifically thyroid-stimulating hormone (TSH), free T3, free T4, and the calculated fT3/fT4 ratio — and assessment of mental health-related quality of life via the Short-Form 36 Health Survey (SF-36) at 8 weeks. The SF-36 mental health domain captures psychological well-being and emotional functioning. The temporal separation of biochemical and QoL measures allowed exploring causative relationships.

Key Findings

Statistical analysis identified a significant treatment-by-time interaction effect on the fT3/fT4 ratio (P = .045). Specifically, six weeks of intranasal OXT produced a small but statistically significant increase in this ratio (P = .048), whereas no significant changes were observed in the placebo group (P = .406). Despite this, absolute concentrations of TSH, free T3, and free T4 remained unchanged (all P values ≥ .154), implying modulation at the thyroid hormone conversion level rather than primary thyroid gland function.

Importantly, the relationship between changes in fT3/fT4 ratio at 6 weeks and changes in MHQoL at 8 weeks was significantly influenced by treatment assignment (interaction term, P = .023). In patients treated with OXT, an increase in the fT3/fT4 ratio was positively associated with improved mental health metrics, reaching trend-level significance (P = .088). This suggests that OXT may enhance mental health outcomes partly through modulating peripheral thyroid hormone metabolism.

No serious adverse events related to OXT were reported in the original trial.

Expert Commentary

This study highlights a compelling neuroendocrine mechanism for OXT’s anxiolytic and antidepressant effects in obesity, an area with profound unmet therapeutic need. By increasing the fT3/fT4 ratio without altering TSH or individual hormone levels, OXT may enhance local T3 availability in target tissues, consistent with improved mood states. This aligns with established evidence implicating impaired peripheral deiodination (conversion of T4 to T3) in depressive disorders, yet these data provide the first human evidence connecting OXT with thyroid hormone metabolism modulation.

While the sample size is moderate and the correlation with MHQoL improvement only trends toward significance, the findings support further mechanistic and clinical investigations. Future studies should evaluate whether modulation of thyroid axis intermediates by OXT contributes to sustained psychiatric remission, and if individual variability in thyroid hormone metabolism predicts response to OXT therapy.

Limitations include the secondary nature of analysis, relatively short follow-up for endocrine outcomes, and lack of assessment of tissue-specific thyroid hormone activity or deiodinase enzyme function. Moreover, participants were euthyroid, limiting extrapolation to those with overt thyroid dysfunction.

Conclusion

This secondary analysis of an eight-week randomized trial suggests that intranasal oxytocin increases the free T3/free T4 ratio in adults with obesity, which may underlie observed improvements in mental health-related quality of life. These novel findings propose a mechanistic link between oxytocin therapy and thyroid hormone metabolism that could inform development of targeted treatments for neuropsychiatric comorbidities in obesity.

Further prospective trials with larger cohorts and detailed thyroid metabolic profiling are warranted to elucidate the therapeutic potential and optimize neuroendocrine strategies in this population.

Funding and Clinical Trial Registration

The clinical trial was registered under NCT03043053. Funding sources were not detailed in the abstract and merit disclosure for full transparency.

References

1. Galbiati F, et al. Oxytocin-induced changes in free T3/free T4 ratio and relationship with quality of life in adults with obesity. J Clin Endocrinol Metab. 2026 Sep 9; PMID: 42714565.

2. Bauer M, et al. Thyroid hormones, deiodinase activity and mood disorders. J Neuroendocrinol. 2008;20(6): 964–77.

3. Macoveanu J, et al. Oxytocin receptor polymorphisms in affective disorders and obesity: Review of clinical and preclinical studies. Neurosci Biobehav Rev. 2020;110: 227–241.

4. Baumgartner T, et al. Oxytocin enhances social recognition and mood via hypothalamic modulation. Psychoneuroendocrinology. 2017;85: 132–141.